Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor

Climacteric

Volumn 11, Issue 3, 2008, Pages 258-264

  Caprio, M ^a,b   Zennaro, M C ^d,e   Feve B ^d   Mammi, C ^a   Fabbri, A ^b,c   Rosano, G ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d INSERM   (France)

^e l'alimentation et l'Environnement   (France)

Author keywords

Adipocyte; Hormone replacement therapy; Mineralocorticoid receptor; Progesterone receptor; Progestogens; Salt sensitivity

Indexed keywords

GESTAGEN; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR;

ADIPOSE TISSUE; ADIPOSE TISSUE CELL; BODY WEIGHT; CELL PROLIFERATION; HUMAN; METABOLIC REGULATION; MOLECULAR INTERACTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SALT SENSITIVITY; SENSITIVITY AND SENSIBILITY;

EID: 48249111825     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802162608     Document Type: Review

References (48)

1. Funder JW, Feldman D, Edelman IS. Specific aldosterone binding in rat kidney and parotid. J Steroid Biochem 1972;3:209-18
2. Feldman D, Funder JW, Edelman IS. Subcellular mechanisms in the action of adrenal steroids. Am J Med 1972;53:545-60
3. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-75
4. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-5
5. Stockand JD. New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol 2002;282:F559-76
6. Pujo L, Fagart J, Gary F, et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat 2007;28:33-40
7. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301
8. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545-56
9. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 2004;217:263-9
10. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005;93:121-5
11. Belmin J, Lévy BI, Michel JB. Changes in the renin-angiotensin- aldosterone axis in later life. Drugs Aging 1994;5:391-400
12. Pechere-Bertschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004;17:994-1001
13. Hernandez Schulman I, Aranda P, Raij L, et al. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006;47:1168-74
14. DeMayo FJ, Zhao B, Takamoto N, Tsai SY. Mechanisms of action of estrogen and progesterone. Ann N Y Acad Sci 2002;955:48-59
15. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9:182-93
16. Souque A, Fagart J, Couette B, et al. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology 1995;136:5651-8
17. Hu X, Funder JW. The evolution of mineralocorticoid receptors. Mol Endocrinol 2006;20:1471-8
18. Leo JCL, Guo C, Woon CT, et al. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 2004;145:1314-21
19. Grecu EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990;46:294-9
20. Funder JW. Mineralocorticoids receptors: distributions and activation. Heart Fail Rev 2005;10:15-22
21. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998;78:783-809
22. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70
23. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998;101:1254-60
24. Penfornis P, Viengchareun S, Le Menuet D, et al. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab 2000;279:E386-94
25. Viengchareun S, Penfornis P, Zennaro MC, Lombes M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001;280:E640-9
26. Caprio M, Fève B, Claës A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185-94
27. Fu M, Sun T, Bookout AL, et al. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol Endocrinol 2005;19:2437-50
28. O'Brien SN, Welter BH, Mantzke KA, Price TM. Identification of progesterone receptor in human subcutaneous adipose tissue. J Clin Endocrinol Metab 1998;83:509-13
29. McDonnell DP, Shahbaz MM, Vegeto E, et al. The human progesterone receptor A form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 1994;48:425-32
30. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 2007;10:19-24
31. Tominaga T, Suzuki H, Ogata Y, et al. The role of sex hormones and sodium intake in postmenopausal hypertension. J Hum Hypertens 1991;5:495-500
32. Zamboni M, Armellini F, Milani MP, et al. Body fat distribution in pre-and post-menopausal women: metabolic and anthropometric variables and their inter-relationship. Int J Obes Relat Metab Disord 1992;16:495-504
33. Lindheim SR, Buchanan TA, Duffy DM, et al. Comparison of estimates of insulin sensitivity in pre- and post-menopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Investig 1994;1:150-4
34. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226-31
35. Pedersen SB, Pedersen SB, Børglum JD, et al. Effects of in vivo estrogen treatment on adipose tissue metabolism and nuclear estrogen receptor binding in isolated rat adipocytes. Mol Cell Endocrinol 1992;85:13-19
36. Hamosh P, Hamosh M, Hamosh P. The effect of estrogen on the lipoprotein lipase activity of rat adipose tissue. J Clin Invest 1975;55:1132-5
37. Homma H, Kurachi H, Nishio Y, et al. Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. J Biol Chem 2000;275:11404-11
38. Tanko LB, Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 2005;258:544-53
39. Purnell JQ, Brandon DD, Isabelle LM, et al. Association of 24h cortisol production rates, cortisol-binding globulin and plasma free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 2004;89:281-7
40. Quresci AC, Bahri A, Breen LA, et al. The influence of the route of estrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 2007;66:632-5
41. Gower BA, Nyman L. Associations among oral estrogen use, free testosterone concentration, and lean body mass among postmenopausal women. J Clin Endocrinol Metab 2000;85:4476-80
42. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645-51
43. Harrison Bernard LM, Hernandez Schulman I, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003;42:1157-63
44. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005;8(Suppl 3):4-12
45. Pizzolo F, Pavan C, Corrocher R, Olivieri O. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 2007;20:1334-7
46. Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006;55:297
47. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-84
48. Szekacs B, Vajo Z, Acs N, et al. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000;7:31-5